Article

Bbarrons.com on 2021-08-30 17:18

Biogen Is Giving Away Its Controversial Alzheimer's Drug: Report 2 min read

Aduhelm costs $56,000 a year and some insurers have been slow to make reimbursements, Reuters reported. Doctors also are questioning the drug's ...

Florida

Related news

BBiogen Stock Tumbles After EU Regulator Has Doubts on Controversial Alzheimer's Therapy1 min read barrons.com
BBiogen to Eliminate Alzheimer's Drug Infrastructure, Search for New CEO1 min read barrons.com
BBiogen in Pole Position After Roche's Alzheimer's Drug Disappoints3 min read barrons.com
Switzerland
BBiogen Says EU Regulator Takes 'Negative Opinion' on Its Alzheimer's Drug1 min read barrons.com
Tokyo Prefecture , Stock Island
BBiogen Is Still a Buy Despite Alzheimer's Drug Concerns, Analyst Says2 min read barrons.com
BBiogen Stock Can Go 'Decisively Higher' on Sales of Alzheimer's Drug2 min read barrons.com
Wall Street
BRoche Sinks as Alzheimer's Drug Disappoints. Biogen is Gaining. 1 min read barrons.com
Switzerland
BBiogen Stock Is Tumbling Because Its Alzheimer's Drug Rollout Isn't Going So Well2 min read barrons.com
Massachusetts , Cambridge , Stock Island
MBiogen and Eisai make plans to take another Alzheimer's drug to the FDA3 min read marketwatch.com
Switzerland , Canton of Solothurn , Japan , San Francisco
BBiogen, Eisai's Alzheimer's Data Confirm Benefit, But Questions Loom2 min read barrons.com
BBiogen Stock Is Down on a Report That Few Have Received Its New Alzheimer's Therapy3 min read barrons.com
Stock Island
BAlzheimer's Drugs May Be a Big-Pharma Payday. Lilly and Biogen Are Facing Off. 4 min read barrons.com
San Francisco
MRegulatory approval is next: Mizuho lifts Biogen to buy on news of Alzheimer's drug success as shares soar2 min read marketwatch.com
Tokyo Prefecture
MOne Alzheimer's drug has failed, but investors are still betting on Biogen and Lilly treatments 2 min read marketwatch.com
Phase 1 , Wall Street
Biogen to cease production of controversial Alzheimer's drug POLITICO
BBiogen Announces New Trial for Alzheimer’s drug Aduhelm2 min read barrons.com
BBiogen Lifts Profit Estimates. The Stock Rises.1 min read barrons.com
MBiogen stock rockets to 6-year high after Alzheimer's drug gets FDA OK4 min marketwatch.com
BA Third Expert Quits FDA Panel Over Approval of Biogen Alzheimer's Drug 2 min barrons.com
BMedicare Will Limit Coverage of Biogen's Alzheimer's Drug2 min read barrons.com